Streetbeat News

Regulatory

MTCH

Tinder, a social media app owned by Match Group (MTCH), is expanding its ID Verification feature to users in the US, UK, Brazil, and Mexico. This feature aims to confirm the authenticity of profiles, focusing on date of birth and likeness, with plans to launch in the US and Mexico by summer, and in the UK and Brazil by spring.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:10 am

AGRI

AgriFORCE Growing Systems Ltd., an AgTech company, announced that the USPTO granted it Patent No. 11,895,958 for 'STRUCTURES FOR GROWING PLANTS (TO GENERATE MICRO-ENVIRONMENT CONDITIONS)' on February 13, 2024.

Portfolio Pulse from Charles Gross

February 20, 2024 | 10:07 am

EVLV

Evolv Technology (NASDAQ:EVLV) announced it is under investigation by the SEC, described as a confidential 'non-public, fact finding inquiry.' The company emphasized its commitment to transparency and cooperation with regulatory bodies, noting the SEC's statement that the investigation does not imply any legal violations.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:06 am

BCRX

BioCryst Pharmaceuticals, Inc. (BCRX) announced the launch of ORLADEYO® in Italy for the prevention of hereditary angioedema (HAE) attacks, following reimbursement and recommendation by the Italian Medicines Agency (AIFA). This marks the availability of the first oral, once-daily therapy for HAE patients in Italy.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:48 am

VST

Vistra received the final regulatory approval from the Federal Energy Regulatory Commission (FERC) for its acquisition of Energy Harbor, which includes a 4,000-megawatt nuclear generation fleet and a retail business of approximately 1 million customers. This acquisition is seen as a significant step in accelerating Vistra's growth in zero-carbon generation.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:20 am

BCS

Barclays has outlined its financial targets for 2024 and beyond, aiming for a RoTE of over 10% in 2024 and around 10.5% excluding inorganic activities. The bank plans to return at least £10bn to shareholders through dividends and buybacks from 2024 to 2026, maintaining stable dividends while increasing buybacks. It targets a Barclays Group NII of approximately £10.7bn, excluding its Investment Bank and Head Office, with a Group total income of around £30bn by 2026. Barclays aims for a cost:income ratio of about 63% in 2024, reducing to the high 50s by 2026, and expects to operate within a CET1 ratio of 13-14%. The bank also anticipates regulatory changes to impact RWAs at the lower end of a 5-10% range.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 7:58 am

EVO

The New Jersey Division of Gaming Enforcement (NJDGE) has concluded its investigation into allegations of misconduct by Evolution AB (EVO) with no further action. The investigation, initiated in November 2021 following a report of misconduct, found no evidence of Evolution's involvement in prohibited jurisdictions. Evolution has also enhanced its compliance processes, which the NJDGE supports.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 7:57 am

FET

Forum Energy Technologies (FET) reported preliminary Q4 results with revenue of $185M, a $6M increase QoQ, and expects adjusted EBITDA of $15M-$17M. The company delays its Q4 and full year 2023 earnings release and investor call to assess potential impacts on income tax and net income due to adjustments in valuation allowance reserves in an international jurisdiction. No significant impact on revenue, adjusted EBITDA, or free cash flow is anticipated. FET plans to issue its full results and host its investor call around March 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 7:40 am

EVTL

Vertical Aerospace (NYSE:EVTL) has received a $10 million grant from the UK Government through the Aerospace Technology Institute (ATI) Programme for developing next-generation propellers for its VX4 aircraft. This marks the third project awarded to Vertical by the ATI Programme, totaling $47 million in UK Government grants, signifying strong governmental support for Vertical's vision in pioneering zero emissions aviation.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 7:18 am

ARGX

The FDA has accepted argenx SE's supplemental Biologics License Application for VYVGART Hytrulo for priority review, targeting chronic inflammatory demyelinating polyneuropathy (CIDP). The PDUFA target action date is set for June 21, 2024. If approved, VYVGART Hytrulo will be the first neonatal Fc receptor blocker for CIDP treatment.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 7:16 am